The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Phase I and Correlative Biology Study of Cilengitide in Patients With Recurrent Malignant Glioma
Open accessAbstract
Purpose: This multi-institutional phase I trial was designed to determine the maximum-tolerated dose (MTD) of cilengitide (EMD 121974) and to evaluate the use of perfusion magnetic resonance imaging (MRI) in patients with recurrent malignant glioma. Patients and Methods: Patients received cilengitide twice weekly on a continuous basis. A treatment cycle was defined as 4 weeks. Treatment-related dose-limiting toxicity (DLT) was defined as any grade 3 or 4 nonhematologic toxicity or grade 4 hematologic toxicity of any duration. Results: A total of 51 patients were enrolled in cohorts of six patients to doses of 120, 240, 360, 480, 600, 1,200, 1,800, and 2,400 mg/m 2 administered as a twice weekly intravenous infusion. Three patients progressed early and were inevaluable for toxicity assessment. The DLTs observed were one thrombosis (120 mg/m 2), one grade 4 joint and bone pain (480 mg/m 2), one thrombocytopenia (600 mg/m 2) and one anorexia, hypoglycemia, and hyponatremia (800 mg/m 2). The MTD was not reached. Two patients demonstrated complete response, three patients had partial response, and four patients had stable disease. Perfusion MRI revealed a significant relationship between the change in tumor relative cerebral blood flow (rCBF) from baseline and area under the plasma concentration versus time curve after 16 weeks of therapy. Conclusion: Cilengitide is well tolerated to doses of 2,400 mg/m 2, durable complete and partial responses were seen in this phase I study, and clinical response appears related to rCBF changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Integrins: A family of cell surface receptors
HYNES, R. (1987) · Cell · doi:10.1016/0092-8674(87)90233-9 · Cited by 4,249
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503
Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00848.x · Cited by 740
Morgan, B., Thomas, A. L., Drevs, J., Hennig, J., Buchert, M., Jivan, A., Horsfield, M. A., Mross, K., Ball, H. A., Lee, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.092 · Cited by 652
Cheresh, D. A. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.18.6471 · Cited by 561
Gladson, C. L., & Cheresh, D. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115516 · Cited by 417
αvβ3 and αvβ5 Integrin Expression in Glioma Periphery
Bello, L., Francolini, M., Marthyn, P., Zhang, J., Carroll, R. S., Nikas, D. C., Strasser, J. F., Villani, R., Cheresh, D. A., & Black, P. M. (2001) · Neurosurgery · doi:10.1097/00006123-200108000-00022 · Cited by 341
MacDonald, T. J., Taga, T., Shimada, H., Tabrizi, P., Zlokovic, B. V., Cheresh, D. A., & Laug, W. E. (2001) · Neurosurgery · doi:10.1097/00006123-200101000-00026 · Cited by 240
Thomas, A. L., Morgan, B., Horsfield, M. A., Higginson, A., Kay, A., Lee, L., Masson, E., Puccio-Pick, M., Laurent, D., & Steward, W. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.034 · Cited by 228
Eskens, F. A. L. M., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Böttcher, S., Wynendaele, W., Drevs, J., Verweij, J., & van Oosterom, A. T. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00057-1 · Cited by 225
Platelet‐derived growth factor in human glioma
Westermark, B., Heldin, C., & Nistér, M. (1995) · Glia · doi:10.1002/glia.440150307 · Cited by 198
Expression of Integrin ανβ3 in Small Blood Vessels of Glioblastoma Tumors
Gladson, C. L. (1996) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199611000-00005 · Cited by 162
Akella, N. S., Twieg, D. B., Mikkelsen, T., Hochberg, F. H., Grossman, S. A., Cloud, G. A., & Nabors, B. (2004) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.20202 · Cited by 83
Self-citationHuman Malignant Glioma Therapy Using Anti-αVβ3 Integrin Agents
Chatterjee, S., Matsumura, A., Schradermeier, J., & Gillespie, G. Y. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006444300504 · Cited by 81
Recurrent malignant glioma in adults
Tatter, S. B. (2002) · Current Treatment Options in Oncology · doi:10.1007/s11864-002-0070-8 · Cited by 52
Kinetic analysis of integrin‐dependent cell adhesion on vitronectin
Germer, M., Kanse, S. M., Kirkegaard, T., Kjøller, L., Felding‐Habermann, B., Goodman, S. L., & Preissner, K. T. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2530669.x · Cited by 40
Cited by
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2748 · Cited by 3,736
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052
Integrins in angiogenesis and lymphangiogenesis
Avraamides, C. J., Garmy-Susini, B., & Varner, J. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2353 · Cited by 1,050
Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
Harjunpää, H., Llort Asens, M., Guenther, C., & Fagerholm, S. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01078 · Cited by 764
Metadata
- Authors
- Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., Fisher, J. D., Cloud, G. A., Zhang, Y., Carson, K., Wittemer, S. M., Colevas, A. D., & Grossman, S. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-05-01
- Volume
- 25
- Issue
- 13
- Pages
- 1651-1657
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2150456585
- Cited by
- 290
- References
- 20
- FWCI
- 15.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.